Literature DB >> 14671160

Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome.

Susan B Nunez1, Karim Calis, Gordon B Cutler, Janet Jones, Penelope P Feuillan.   

Abstract

We administered the aromatase inhibitor fadrozole to 16 girls with gonadotropin-independent precocious puberty due to the McCune-Albright syndrome. The girls' ages ranged from 3.2-9.7 yr, and their bone ages ranged from 5.75-14.25 yr. After baseline evaluations, fadrozole was started at a dose of 240 microg/kg.d (equivalent to the dose recommended for therapy of estrogen-dependent breast cancer) for 12-21 months and increased to 480 microg/kg.d for an additional 12 months in 10 girls. During treatment, seven girls had evidence of central precocious puberty; hence, the GnRH agonist deslorelin (4 microg/kg.d sc) was added to their regimen. One girl was on a long-acting GnRH agonist from the start of treatment. Patients were evaluated at 2-6-month intervals throughout treatment. After the first 6-12 months of treatment, fadrozole showed some benefits in 10 girls, including decrease in frequency of menses and/or rates of linear growth and bone maturation; however, fadrozole had no significant benefit in the group as a whole. The seven girls with evidence of central precocious puberty had no slowing in the progression of their puberty during the combined fadrozole and GnRH analog treatment. Adverse effects of fadrozole included inhibition of cortisol and aldosterone biosynthesis at the dose of 480 microg/kg.d, without clinical evidence of adrenal insufficiency. In addition, three patients complained of nonspecific abdominal pain during fadrozole treatment. In one patient, this resolved with a reduction in dose from 480 to 240 microg/kg.d; in two patients, it resolved spontaneously. One girl had muscle weakness and constipation on the 480 microg/kg.d. This resolved after discontinuation of the drug. We conclude that fadrozole is not sufficiently potent to block estrogen synthesis in most girls with gonadotropin-independent precocious puberty due to the McCune-Albright syndrome and may impair the adrenocortical stress response.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14671160     DOI: 10.1210/jc.2003-030864

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Treatment of Peripheral Precocious Puberty.

Authors:  Melissa Schoelwer; Erica A Eugster
Journal:  Endocr Dev       Date:  2015-12-17

2.  Treatment of Girls and Boys with McCune-Albright Syndrome with Precocious Puberty - Update 2017.

Authors:  Anna Neyman; Erica A Eugster
Journal:  Pediatr Endocrinol Rev       Date:  2017-12

Review 3.  Aromatase inhibitors in pediatrics.

Authors:  Jan M Wit; Matti Hero; Susan B Nunez
Journal:  Nat Rev Endocrinol       Date:  2011-10-25       Impact factor: 43.330

Review 4.  Treatment of precocious puberty in McCune-Albright syndrome.

Authors:  Jakub Mieszczak; Erica A Eugster
Journal:  Pediatr Endocrinol Rev       Date:  2007-08

5.  Long-term outcomes of letrozole treatment for precocious puberty in girls with McCune-Albright syndrome.

Authors:  Andrea Estrada; Alison M Boyce; Beth A Brillante; Lori C Guthrie; Rachel I Gafni; Michael T Collins
Journal:  Eur J Endocrinol       Date:  2016-08-25       Impact factor: 6.664

6.  Eight-year follow-up of a girl with McCune-Albright syndrome.

Authors:  Zehra Aycan; Aşan Önder; Semra Çetinkaya
Journal:  J Clin Res Pediatr Endocrinol       Date:  2011-02-23

7.  Fulvestrant treatment of precocious puberty in girls with McCune-Albright syndrome.

Authors:  Emily K Sims; Sally Garnett; Franco Guzman; Françoise Paris; Charles Sultan; Erica A Eugster
Journal:  Int J Pediatr Endocrinol       Date:  2012-09-22

Review 8.  Peculiarities of Precocious Puberty in Boys and Girls With McCune-Albright Syndrome.

Authors:  Domenico Corica; Tommaso Aversa; Giorgia Pepe; Filippo De Luca; Malgorzata Wasniewska
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-22       Impact factor: 5.555

9.  Clinical and endocrine characteristics and genetic analysis of Korean children with McCune-Albright syndrome: a retrospective cohort study.

Authors:  Eun-Kyung Cho; Jinsup Kim; Aram Yang; Chang-Seok Ki; Ji-Eun Lee; Sung Yoon Cho; Dong-Kyu Jin
Journal:  Orphanet J Rare Dis       Date:  2016-08-09       Impact factor: 4.123

Review 10.  Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation.

Authors:  Alison M Boyce; Michael T Collins
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.